Announced
Financials
Tags
Pending
Switzerland
Acquisition
Cross Border
Friendly
Private
Single Bidder
Majority
Biotechnology
biotechnology company
Private Equity
Synopsis
Atlas Antibodies, a developer of novel antibodies, agreed to acquire evitria, an operator of a biotechnology firm, from Afinum and SHS for £170m. “After successfully building and continuously improving our expression platform over the last ten years, we look forward to this next phase in our company’s development. We have only recently started to more actively pursue opportunities on a global basis, and look forward to continuing on this growth journey backed by the team around Atlas Antibodies and Patricia Industries," Christian Eberle, evitria CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.